14 results
8-K
EX-99.2
XLO
Xilio Therapeutics Inc
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
mission to improve the lives of patients with cancer.”
Exclusive License Agreement with Gilead
As previously announced today, Xilio entered
8-K
EX-99.2
XLO
Xilio Therapeutics Inc
9 Nov 22
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
7:45am
area for citations and references Pioneering Tumor - Activated Immuno - Oncology Therapies to Pursue Positive Outcomes for More Patients Mission Design
10-K
1swsrbdokwh17u2rm2z7
1 Mar 22
Annual report
4:07pm
8-K
EX-99.1
uh9yx
6 Jan 22
Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors
7:45am
10-Q
4pary
2 Dec 21
Quarterly report
4:15pm
424B4
rkpmuh7u o61
22 Oct 21
Prospectus supplement with pricing info
4:02pm
S-1/A
sr9lhhyhc5u
18 Oct 21
IPO registration (amended)
6:04am
S-1
mi7kx2lhdo xj1h
1 Oct 21
IPO registration
4:49pm
DRS/A
zn4qf5 e2ji5u
14 Sep 21
Draft registration statement (amended)
12:00am
DRS
2bgf gjy9x
24 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next